Shares of Exact Science Corp. (EXAS) surged on Tuesday after the FDA said it had approved the company's new colorectal screening product. The U.S. Food and Drug administration has approved its Cologuard test, a non-invasive way to screen for colorectal cancer at home. Kevin Conroy is the Chairman, CEO and President of the company and told TheStreet's Susannah Lee it was a long road in the making. Conroy also said this was the first time in history the Centers for Medicare and Medicaid Services proposed national coverage on the same day as the FDA approval for a technology. Conroy also shared with TheStreet what Exact Sciences has in the product pipeline. Conroy says the company is working on a similar test for pancreatic cancer.